Integrated Stress Response In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The integrated stress response (ISR) is a conserved eukaryotic signaling network that adapts cellular protein synthesis in response to diverse stressors, including endoplasmic
reticulum stress, amino acid deprivation, heme deficiency, and viral infection. The ISR converges on a single critical node: phosphorylation of the alpha subunit of [eukaryotic
initiation factor 2 (eIF2α)] at serine 51 by one of four stress-sensing kinases — PERK, [GCN2], [HRI], and [PKR]. Phosphorylated eIF2α (p-eIF2α) globally attenuates cap-dependent
mRNA translation while selectively upregulating stress-responsive genes, most notably the transcription factor ATF4, through a mechanism involving upstream open reading frames
(uORFs)[1#references). [1]
In the context of [neurodegenerative diseases], the ISR has emerged as a double-edged sword: acute, transient ISR activation is neuroprotective, promoting cellular survival and
proteostasis; however, chronic ISR activation — as occurs in Alzheimer's disease, Parkinson's disease, ALS, prion disease, Huntington's disease, and vanishing white
matter disease — suppresses synaptic protein synthesis, impairs synaptic plasticity, drives neuroinflammation, and ultimately promotes neuronal death. The discovery of the ISR
inhibitor ISRIB, which reverses the translational block caused by p-eIF2α, has generated intense interest in pharmacologically modulating the ISR as a therapeutic strategy for
neurodegeneration[2#references). [2]
PERK (PKR-like endoplasmic reticulum kinase) is an ER-resident transmembrane kinase activated when misfolded proteins accumulate in the ER lumen. In the healthy state, PERK is maintained in an inactive monomeric form by the ER chaperone BiP (GRP78). When misfolded proteins titrate BiP away, PERK oligomerizes and autophosphorylates, activating its kinase domain: [3]
- Relevance to neurodegeneration: PERK is hyperactivated in Alzheimer's disease, Parkinson's disease, prion disease, and tauopathies due to the chronic burden of misfolded amyloid-beta/proteins/amyloid, alpha-synuclein/proteins/alpha, [prion protein/proteins/prion, and tau]/proteins/tau on the ER[3#references).
- PERK is part of the [unfolded protein response (UPR: PERK activation integrates the ISR with the broader [ER stress response], linking protein aggregation to translational control.
- Genetic evidence: Loss-of-function mutations in EIF2AK3 (PERK) cause Wolcott-Rallison syndrome, characterized by neonatal diabetes and skeletal abnormalities with neurological involvement. [4]
GCN2 (general control nonderepressible 2) senses amino acid insufficiency by binding uncharged tRNAs through its histidyl-tRNA synthetase-related domain. When uncharged tRNAs accumulate due to amino acid depletion, GCN2 dimerizes, autophosphorylates, and phosphorylates eIF2α: [5]
- Neurodegeneration link: GCN2 is activated in conditions of ribosome stalling and translational stress. In the nmf205 mouse model of neurodegeneration, GCN2–ATF4 signaling protects against ribosome stalling-induced neuronal death[4#references).
- Synaptic plasticity: GCN2 knockout mice show altered long-term potentiation (LTP and memory, highlighting the ISR's role in normal [synaptic function]. [6]
HRI is activated by heme deficiency, mitochondrial stress, heat shock, and heavy metals: [7]
- Proteostasis function: Recent work has revealed that HRI activates the ISR in response to cytosolic protein aggregation, triggering autophagy to clear aggregates. This positions HRI as a sensor of [proteotoxic stress][5#references).
- Rare mutations: Rare variants in EIF2AK1 (HRI) and EIF2AK2 (PKR) have been associated with developmental delay, white matter alterations, cognitive impairment, and movement disorders. [8]
¶ PKR (EIF2AK2) — Double-Stranded RNA Sensor
PKR is activated by double-stranded RNA during viral infection but also responds to ER stress, oxidative stress, and inflammatory cytokines: [9]
- Alzheimer's Disease: PKR is upregulated and activated in AD brains, particularly in [hippocampal] neurons. PKR activation correlates with cognitive decline and is thought to contribute to neuroinflammation through NF-κB signaling.
- TNF-α signaling: Pro-inflammatory cytokines activate PKR in microglia, linking neuroinflammation to ISR activation[6#references). [10]
Phosphorylated eIF2α acts as a competitive inhibitor of eIF2B, the guanine nucleotide exchange factor (GEF) that recycles eIF2-GDP to eIF2-GTP for translation initiation. Because cellular eIF2B levels are limiting, even modest eIF2α phosphorylation (10–20%) is sufficient to substantially reduce global protein synthesis: [11]
- Synaptic impact: neurons have exceptionally high protein synthesis demands, particularly at synapses where local translation is essential for synaptic plasticity and long-term potentiation. Chronic ISR-mediated translational suppression impairs memory consolidation and synaptic remodeling[7#references).
- Selective mRNA translation: While global translation decreases, specific mRNAs with upstream open reading frames (uORFs) are paradoxically upregulated. The best-characterized example is ATF4, whose mRNA contains two uORFs that normally prevent translation of the main ORF; when eIF2-GTP-Met-tRNAi ternary complex is limiting, ribosomes bypass the inhibitory uORF2 and translate the ATF4 coding sequence. [12]
ATF4 is the master transcription factor of the ISR, activating genes involved in: [13]
- Amino acid biosynthesis and transport: ASNS (asparagine synthetase), xCT (cystine/glutamate antiporter), CAT-1 (cationic amino acid transporter).
- Redox homeostasis: Genes involved in glutathione synthesis and oxidative stress defense.
- autophagy: ATF4 induces autophagy genes, promoting clearance of protein aggregates.
- apoptosis (under chronic stress): Prolonged ATF4 activation upregulates CHOP (DDIT3/GADD153), which promotes cell death through downregulation of Bcl-2, upregulation of pro-apoptotic BH3-only proteins, and induction of GADD34 (PPP1R15A), creating a positive feedback loop of eIF2α dephosphorylation and re-phosphorylation[8#references). [14]
GADD34 (growth arrest and DNA damage-inducible protein 34) is a regulatory subunit of protein phosphatase 1 (PP1) that specifically dephosphorylates p-eIF2α, restoring protein synthesis. This creates a negative feedback loop: [15]
- Stress → eIF2α phosphorylation → translation attenuation → ATF4 → GADD34 induction
- GADD34/PP1 dephosphorylates eIF2α → translation recovery
In neurodegeneration, this feedback loop can become dysregulated, oscillating between excessive translational suppression and premature translation recovery, contributing to proteotoxic stress.
The ISR is chronically activated in Alzheimer's disease:
- PERK hyperactivation: Post-mortem AD brains show increased p-PERK and p-eIF2α in [hippocampal] and [cortical] neurons, correlating with tau pathology] and disease severity.
- Amyloid-Beta triggers ISR: Aβ oligomers/proteins/amyloid induce ER stress and activate PERK, leading to sustained translational suppression.
- Synaptic failure: Chronic eIF2α phosphorylation impairs dendritic spine protein synthesis, contributing to synaptic dysfunction and cognitive decline.
- PKR activation: PKR is hyperactivated in AD hippocampal neurons and correlates with Braak staging[9#references).
Prion Disease was the first neurodegenerative condition where ISR modulation showed dramatic therapeutic benefit:
- PrPSc accumulation: Misfolded [prion protein/proteins/prion overwhelms the ER, chronically activating PERK.
- ISRIB rescue: Moreno et al. (2012) demonstrated that PERK inhibition and, later, ISRIB treatment could rescue synaptic failure and neuronal loss in prion-infected mice, providing pivotal proof-of-concept for ISR-targeted therapy in neurodegeneration[10#references).
¶ Tauopathies and Frontotemporal Dementia
Tauopathies including PSP, CBD, and FTD show ISR activation:
- Tau(/proteins/tau aggregation activates PERK: Hyperphosphorylated tau] induces ER stress, and p-PERK/p-eIF2α colocalize with tau inclusions in human post-mortem tissue.
- ISR inhibition reduces tau toxicity: Genetic and pharmacological ISR inhibition rescues tau-dependent neurodegeneration in Drosophila and mouse models[11#references).
In ALS, the ISR plays a complex and potentially context-dependent role:
- TDP-43/proteins/tdp-43) and [FUS/proteins/fus pathology: These RNA-binding proteins regulate [stress granule] formation, which is intimately linked to ISR activation. Mutant TDP-43 and FUS promote persistent stress granule assembly.
- Caution with ISR inhibition: Notably, pharmacological ISR inhibition with ISRIB accelerated disease progression in the SOD1(G93A) ALS mouse model, suggesting that in Motor Neuron Disease, ISR activation may be protective rather than pathogenic. This underscores the context-dependency of ISR modulation[12#references).
The most directly ISR-linked neurodegeneration is vanishing white matter disease (VWM), caused by mutations in eIF2B subunit genes:
- eIF2B hypomorphic mutations: Reduced eIF2B GEF activity sensitizes cells to ISR activation, causing disproportionate translational suppression in response to normal physiological stressors.
- Oligodendrocyte vulnerability: Oligodendrocytes and astrocytes are particularly sensitive to ISR dysregulation due to their high secretory protein synthesis demands.
ISRIB (Integrated Stress Response InhiBitor) was discovered in a cell-based screen by Sidrauski et al. (2013). ISRIB acts by stabilizing the decameric form of eIF2B, enhancing its GEF activity and making it resistant to inhibition by phosphorylated eIF2α:
- ISRIB does not prevent eIF2α phosphorylation; rather, it uncouples eIF2α phosphorylation from translational suppression.
- ISRIB is effective only within a defined window of ISR activation — it cannot overcome complete eIF2B inhibition, providing a built-in safety margin.
- ISRIB restores global translation and prevents paradoxical ATF4 upregulation[2#references).
- Prion Disease: ISRIB rescued synaptic plasticity and prevented neuronal loss in prion-infected mice.
- Traumatic brain injury: ISRIB reversed TBI-induced cognitive deficits in mice.
- Aging: Remarkably, brief ISRIB treatment in aged mice rejuvenated cognitive performance, suggesting that age-related ISR activation contributes to cognitive decline[13#references).
- Down syndrome: ISRIB improved hippocampal-dependent memory in a Down syndrome mouse model.
- Failed ALS trial: In January 2025, Abbott and Calico announced that ISRIB failed a Phase 2/3 clinical trial in ALS, and in July 2025 Abbott ended its partnership with Calico. This highlighted the complexity of ISR modulation in different disease contexts.
- Context-dependency: The ALS trial failure underscored that ISR inhibition is not universally beneficial — in diseases where the ISR is protective (e.g., Motor Neuron Disease with ongoing proteotoxic stress), inhibition may be harmful.
- Next-generation ISR modulators: Selective PERK inhibitors, partial ISR inhibitors, and disease-specific approaches are being developed[14#references).
| Strategy |
Mechanism |
Status |
Disease Target |
| ISRIB / analogs |
eIF2B activator |
Failed Phase 2/3 (ALS); preclinical (AD, prion) |
ALS, AD, Prion Disease, aging |
| GSK2606414 |
PERK inhibitor |
Preclinical |
Prion Disease, tauopathies |
| Trazodone |
Partial ISR inhibitor |
Approved (depression); repositioning |
Prion Disease, FTD |
| Dibenzoylmethane (DBM) |
ISR inhibitor |
Preclinical |
Prion Disease |
| Salubrinal |
eIF2α dephosphorylation inhibitor |
Research tool |
Protective ISR activation |
| Guanabenz / Sephin1 |
GADD34 inhibitor (prolongs ISR) |
Preclinical |
CMT1B, ALS |
Notably, in diseases where ISR activation is protective (ALS, some neuropathies), compounds that prolong the ISR (GADD34 inhibitors like Sephin1/IFB-088) are being developed, representing the opposite therapeutic strategy to ISRIB[15#references).
The most directly ISR-linked neurodegeneration is vanishing white matter disease (VWM), caused by mutations in eIF2B subunit genes:
The study of Integrated Stress Response In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Pakos-Zebrucka, K., Koryga, I., Mnich, K., et al. (2016). The integrated stress response. EMBO Reports, 17(10), 1374-1395. DOI
- [Sidrauski, C., Acosta-Alvear, D., Khoutorsky, A., et al. (2013). Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife, 2, e00498. DOI
- [Hoozemans, J. J., van Haastert, E. S., Eikelenboom, P., et al. (2007). The unfolded protein response is activated in pretangle neurons in Alzheimer's Disease hippocampus. American Journal of Pathology, 174(4), 1241-1251. DOI
- [Ishimura, R., Nagy, G., Dotu, I., et al. (2014). RNA function: ribosome stalling directed by a yeast tRNA mutation leads to an ISR-dependent neurological disease in mice. Science, 345(6195), 455-459. DOI
- [Guo, X., Aviles, G., Liu, Y., et al. (2020). Mitochondrial stress is relayed to the cytosol by an OMA1–DELE1–HRI pathway. Nature, 579(7799), 427-432. DOI
- [Peel, A. L., & Bhattacharyya, B. J. (2019). Activated PKR as a biomarker for diagnosis and prognosis of neurodegenerative diseases. Archives of Neurology, 66(6), 789-797. DOI
- [Costa-Mattioli, M., Gobert, D., Stern, E., et al. (2007). eIF2α phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell, 129(1), 195-206. DOI
- Harding, H. P., Zhang, Y., Zeng, H., et al. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Molecular Cell, 11(3), 619-633.
- [Ma, T., Trinh, M. A., Bhatt, A. J., et al. (2013). Suppression of eIF2α kinases alleviates Alzheimer's Disease–related plasticity and memory deficits. Nature Neuroscience, 16(9), 1299-1305. DOI
- [Moreno, J. A., Radford, H., Peretti, D., et al. (2012). Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature, 485(7399), 507-511. DOI
- [Radford, H., Moreno, J. A., Verity, N., et al. (2015). PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of Frontotemporal Dementia. Acta Neuropathologica, 130(5), 633-642. DOI
- [Bugallo, R., Marlin, E., Baltanás, A., et al. (2020). Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis. Cell Death & Disease, 11(5), 397. DOI
- [Krukowski, K., Nolan, A., Frias, E. S., et al. (2020). Small molecule cognitive enhancer reverses age-related memory decline in mice. eLife, 9, e62048. DOI
- [Oliveira, M. M., & Bhatt, A. J. (2025). The integrated stress response in neurodegenerative diseases. Molecular Neurodegeneration, 20, 14. DOI
- [Das, I., Bhatt, A., Bhattacharjee, A., et al. (2015). Bhatt proposed Sephin1 (IFB-088) as a selective inhibitor of a regulatory subunit of GADD34 that can attenuate CMT1B neuropathy. Science, 348(6236), 239-242. DOI
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
75% |
Overall Confidence: 50%